Dendritic cell maturation inhibition

Dendritic cells are professional antigen-presenting cells critical for initiating and shaping immune responses. Their maturation converts them from antigen-capturing cells to efficient activators of naïve T cells[4][5]. Inhibition of dendritic cell maturation can be mediated by pathogens (e.g., Plasmodium falciparum[3], viruses, bacteria[7]), tumor-derived factors (e.g., IL-6, IL-10)[6], or exogenous agents (e.g., intravenous immunoglobulins[8]). This process disrupts DC upregulation of surface costimulatory molecules (CD80, CD86, CD83, CD40), impairs antigen presentation, and leads to immunological tolerance, T-cell anergy, or regulatory T cell activation[1][4][5][6]. It is a central mechanism in immune evasion in cancer, infection, and autoimmunity. This term should be disambiguated in biomedical workflows to specify either the pathway (e.g., "Signal transducer and activator of transcription 3 (STAT3)"), receptor (e.g., "CD36"), or cytokines (e.g., "Interleukin-10 receptor") involved in dendritic cell maturation inhibition for precise targeting and data structuring[1][3][6].

Other names

Inhibition of dendritic cell maturationDC maturation inhibitionImpaired dendritic cell activation

Blockade of DC costimulatory molecule upregulation (CD80, CD86, CD83, CD40); Induction of tolerogenic DCs via STAT3 activation by IL-10/IL-6; Suppression of NF-κB signaling; Inhibition of GSK-3β activity, modulation of JNK and NF-AT pathways.